Can I Take St. John's Wort with Wegovy?

What Is St. John's Wort and Why Does It Affect So Many Drugs?

St. John's Wort is a flowering plant used widely for mild-to-moderate depression and anxiety. Standardized extracts typically contain 0.3% hypericin and 3 to 5% hyperforin. Hyperforin is the constituent most responsible for drug interactions; it activates the pregnane X receptor (PXR), which then upregulates the expression of CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (P-gp) [1].

The Scale of the Interaction Problem

The FDA's 2020 guidance on drug interaction studies specifically names St. John's Wort as a "clinically significant" inducer of CYP3A4 [2]. That designation is based on decades of documented cases: a 2000 letter in The Lancet identified 10 organ-transplant patients whose cyclosporine trough levels fell by 30 to 64% after they began taking the supplement [3]. A systematic review published in the British Journal of Clinical Pharmacology analyzed 54 clinical studies and found that St. John's Wort reduced plasma concentrations of CYP3A4 substrates by a median of 48% [4].

Why the Induction Window Matters

Enzyme induction is not immediate. CYP3A4 upregulation typically reaches its maximum effect after 10 to 14 days of daily St. John's Wort use [5]. When someone stops taking it, the induction effect persists for roughly 2 weeks while newly synthesized enzyme is cleared. This means the interaction window extends both before and after active supplement use.

How Is Semaglutide 2.4 mg Actually Metabolized?

Semaglutide is a fatty-acid-acylated GLP-1 analogue. Its pharmacokinetic profile differs substantially from small-molecule drugs. Understanding that profile is the first step in assessing any interaction risk.

Proteolytic Degradation, Not CYP Enzymes

The Wegovy prescribing information filed with the FDA states that semaglutide "is metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain" [6]. CYP enzymes do not play a meaningful role. Semaglutide is not a substrate of CYP3A4, CYP2C9, or P-gp in clinically significant amounts.

Albumin Binding and Half-Life

Semaglutide binds strongly to albumin (greater than 99%), which extends its half-life to approximately 168 hours (7 days) and allows once-weekly dosing [6]. Albumin binding is not a site of interaction with St. John's Wort because hyperforin does not competitively displace peptide ligands at albumin to a clinically meaningful degree [7].

Renal and Biliary Clearance

After proteolytic cleavage, semaglutide-derived metabolites are excreted via urine and feces. A mass-balance study (N=7) using radiolabeled semaglutide found 75% of radioactivity recovered in urine and 25% in feces, with no intact parent drug detected in urine [6]. Biliary transport proteins such as OATP1B1 are upregulated by St. John's Wort, but semaglutide metabolites are not recognized substrates of these transporters in reported in-vitro assays [7].

Direct Pharmacokinetic Interaction: Low, but Not Zero Risk

Given semaglutide's non-CYP metabolism, the direct pharmacokinetic interaction between St. John's Wort and Wegovy is considered low [8]. No published clinical trial has specifically studied the combination. The absence of direct trial data cuts both ways: it does not prove safety, and it does not prove harm.

What the Mechanistic Models Suggest

Physiologically-based pharmacokinetic (PBPK) modeling has been applied to semaglutide by Novo Nordisk in support of its FDA submission. Those models did not flag CYP3A4 induction as a relevant concern for the parent molecule [6]. A 2021 review in Clinical Pharmacokinetics specifically noted that GLP-1 receptor agonists as a class have "minimal potential for cytochrome P450-mediated drug interactions" due to their peptidic nature [8].

Where a Direct Effect Could Theoretically Appear

St. John's Wort increases gastric motility modestly in some subjects [9]. Semaglutide slows gastric emptying, an effect most pronounced in the first 4 to 8 weeks of therapy [6]. These opposing effects on gastric motility could theoretically alter the absorption of orally co-administered drugs in unpredictable ways. Neither agent changes its own absorption materially through this mechanism, but oral medications taken alongside both agents may be affected [9].

Indirect Pharmacodynamic Risks: The Real Clinical Concern

The more important interaction is indirect. People taking Wegovy for weight management often carry several comorbidities. They may be on antidepressants, oral contraceptives, anticoagulants, antiepileptics, or immunosuppressants. St. John's Wort can substantially reduce the blood levels of all of these drug classes [4].

Antidepressants and Serotonin Syndrome

St. John's Wort inhibits reuptake of serotonin, dopamine, and norepinephrine [1]. When combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), the risk of serotonin syndrome increases. A case series published in the British Medical Journal documented five patients who developed serotonin syndrome-like reactions after adding St. John's Wort to their existing SSRI regimen [10]. Depression is common in individuals with obesity; the STEP-1 trial (N=1,961) found that roughly 14% of semaglutide-treated participants reported a baseline history of depression [11].

Oral Contraceptives

St. John's Wort reduces ethinylestradiol and norethindrone plasma concentrations by approximately 13 to 15% through CYP3A4 and P-gp induction [12]. The European Medicines Agency issued a public statement warning that this interaction may reduce contraceptive efficacy and lead to unintended pregnancy [13]. Women of reproductive age using Wegovy who also rely on hormonal contraception should be counseled about this risk explicitly.

Warfarin and Other Anticoagulants

A prospective pharmacokinetic study found that 14 days of St. John's Wort (300 mg three times daily) reduced warfarin AUC by 24% and lowered INR by a mean of 1.0 units in healthy volunteers [4]. Patients taking warfarin alongside Wegovy who self-start St. John's Wort without telling their physician could experience clinically significant drops in anticoagulant coverage.

Antiepileptic Drugs

Carbamazepine, phenytoin, and valproate are all either CYP3A4 substrates or inducers themselves. Adding St. John's Wort to these regimens can produce unpredictable changes in seizure threshold [5]. The American Epilepsy Society does not recommend concurrent use [5].

What the STEP Trials Tell Us About Semaglutide's Own Interaction Profile

The STEP clinical program is the primary evidence base for Wegovy's safety and efficacy. STEP-1 (N=1,961) demonstrated 14.9% mean body weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo (P<0.001) [11]. STEP-2 (N=1,210) enrolled patients with type 2 diabetes and reported 9.6% weight loss [14]. Across all four STEP trials, no formal drug interaction signal with herbal supplements was reported because supplement use was not systematically tracked. That gap in the data is itself clinically relevant: it means no safety signal was identified, but none was actively sought either.

Adverse Events Relevant to Supplement Co-Use

Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common reasons for discontinuation in STEP-1, affecting 4.5% of participants [11]. St. John's Wort independently causes gastrointestinal upset in 0.5 to 2% of users, per post-marketing surveillance data [1]. Co-use may compound GI tolerability problems during Wegovy's dose-escalation phase, though this has not been studied head-to-head.

Pharmacokinetic Summary Table

| Parameter | Semaglutide 2.4 mg | St. John's Wort (Hyperforin) | |---|---|---| | Primary metabolism | Proteolytic cleavage, beta-oxidation | CYP3A4 substrate and inducer | | CYP3A4 interaction | Not a substrate | Potent inducer (via PXR activation) | | P-gp interaction | Minimal | Inducer | | Half-life | ~168 hours | ~9 hours (hyperforin) | | Protein binding | >99% albumin | ~99% albumin | | Direct PK interaction risk | Low | N/A (the inducer agent) |

Clinical Decision Framework: What to Do If You Are Already Taking Both

The following stepwise approach reflects consensus from published drug interaction guidance [2] and GLP-1 receptor agonist prescribing data [6]. It is not a substitute for individualized medical advice.

Step 1: Inventory All Co-Medications

Before making any change, list every prescription drug, over-the-counter medication, and supplement you take. Identify which of those are CYP3A4 substrates (examples: oral contraceptives, statins, some antidepressants, cyclosporine, warfarin). Any drug on that list represents a potential St. John's Wort interaction risk independent of Wegovy [4].

Step 2: Assess the Indication for St. John's Wort

St. John's Wort is most commonly used for mild-to-moderate depression. The American Psychiatric Association's practice guideline for major depressive disorder notes that for mild-to-moderate cases, licensed pharmacological agents (SSRIs, bupropion) or structured psychotherapy are preferred first-line options [15]. If your prescriber agrees the indication is valid, they may recommend a licensed antidepressant instead, which allows them to monitor drug levels and adjust dosing.

Step 3: Do Not Stop Abruptly Without Guidance

Stopping St. John's Wort abruptly after long-term use can alter the plasma concentrations of any CYP3A4-substrate co-medications you take, sometimes sharply upward, as the induction effect reverses over approximately 14 days [5]. Warfarin INR could rise. Cyclosporine levels could spike. Coordinate any tapering with your prescriber.

Step 4: If You Continue Both, Increase Monitoring

If stopping St. John's Wort is not immediately feasible, more frequent monitoring of relevant lab values (INR for warfarin, drug levels for cyclosporine or antiepileptics, blood pressure for antihypertensives) is appropriate. No specific monitoring protocol for the semaglutide-St. John's Wort pair exists in published guidelines, because the direct interaction risk for semaglutide itself is low [8].

What Prescribers Need to Know: Disclosure Gaps in Clinical Practice

Studies of herbal supplement disclosure show that 40 to 70% of patients do not tell their physicians they are taking herbal products [16]. A 2017 systematic review in PLOS ONE (N=65 studies, over 150,000 patients) found that the pooled non-disclosure rate for herbal supplement use was 63% [16]. Patients prescribed Wegovy are no exception. Routine screening at every visit for herbal and over-the-counter supplement use should be standard practice for any prescriber managing a GLP-1 receptor agonist program.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states that "a comprehensive medication review including herbals and supplements should precede initiation of any anti-obesity pharmacotherapy" [17]. Repeating that review at each dose-escalation visit is good clinical practice.

Semaglutide Dose Escalation and the Interaction Window

Wegovy is started at 0.25 mg weekly and escalated over 16 to 20 weeks to the maintenance dose of 2.4 mg weekly [6]. During the escalation phase, patients may be more vulnerable to compounding GI side effects from any supplement that independently irritates the gut. St. John's Wort's GI effects are dose-dependent and more pronounced at the 900 mg/day doses sometimes used for depression [1]. Starting or stopping St. John's Wort during the escalation phase complicates symptom attribution: if nausea worsens, the prescriber cannot easily tell whether it reflects semaglutide dose-escalation or a supplement effect.

A Note on Oral Semaglutide (Rybelsus) Versus Wegovy

Oral semaglutide (Rybelsus, 7 mg or 14 mg tablets) uses an absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, SNAC) to support absorption in the stomach. The FDA prescribing information for Rybelsus notes that gastric pH and motility changes can alter SNAC-mediated absorption [18]. St. John's Wort's modest pro-motility effect could theoretically reduce Rybelsus absorption more than it affects subcutaneous Wegovy, though no clinical data confirm this. Patients switching between formulations should inform their prescriber of any supplement use before the transition [18].

Summary of Evidence Quality

The direct semaglutide-St. John's Wort interaction has not been studied in a dedicated clinical pharmacokinetics trial. Evidence quality for the direct PK interaction is Level 4 (mechanistic inference from metabolic pathway data). Evidence for St. John's Wort's effect on CYP3A4 substrates in general is Level 1a, based on multiple randomized pharmacokinetic crossover studies and systematic reviews [4]. The clinical decision to avoid concurrent use is therefore driven primarily by the established interaction risk St. John's Wort poses to co-medications, not by a proven direct effect on semaglutide itself.